Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splicing regulatory glutamic acid and lysine rich protein 1 (SREK1) is a member of the serine/arginine-rich (SR) protein family that contains RNA recognition motifs and plays a key role in the regulation of alternative splicing by modulating the activity of other SR proteins. The protein inhibits the splicing activity of specific splice factors such as SFRS1, SFRS2, and SFRS6, while augmenting splicing by SFRS3. SREK1 is predicted to have nucleic acid binding and nucleotide binding activity, be localized to the nucleus and nucleoplasm, and act orthologously in humans, zebrafish, and other species. Although the gene is fundamental for post-transcriptional modification, it is not currently considered a therapeutic drug target nor associated with prominent disease mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing regulatory glutamic acid and lysine rich protein 1 (SREK1).